SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-000786 to ProSomnus, Inc. (CIK 0001934064)

ProSomnus, Inc. (CIK 0001934064)
Date: Jan. 24, 2023 · CIK: 0001934064 · Accession: 0000000000-23-000786

AI Filing Summary & Sentiment

File numbers found in text: 333-269156

Date
January 24, 2023
Author
Not clearly detected
Form
UPLOAD
Company
ProSomnus, Inc. (CIK 0001934064)

Letter

United States securities and exchange commission logo January 24, 2023 Len Liptak Chief Executive Officer ProSomnus, Inc. 5860 West Las Positas Blvd., Suite 25 Pleasanton, California, 94588 Re:ProSomnus, Inc. Registration Statement on Form S-1 Filed January 9, 2023 File No. 333-269156 Dear Len Liptak: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Form S-1 filed January 9, 2023 Cover Page 1.For each of the securities being registered for resale, disclose the price that each of the selling security holders paid for such securities. 2.Disclose the exercise price of the warrants compared to the market price of the underlying Common Stock. If the warrants are out the money, please disclose the likelihood that warrant holders will not exercise their warrants. Provide similar disclosure in the prospectus summary, risk factors, MD&A and use of proceeds section and disclose that cash proceeds associated with the exercises of the warrants are dependent on the stock price. As applicable, describe the impact on your liquidity and update the discussion on the ability of your company to fund your operations on a prospective basis with your current cash on hand.

FirstName LastNameLen Liptak Comapany NameProSomnus, Inc. January 24, 2023 Page 2 FirstName LastNameLen Liptak ProSomnus, Inc. January 24, 2023 Page 2 3.We note the significant number of redemptions of your Common Stock in connection with your business combination and that the shares being registered for resale will constitute a considerable percentage of your public float. We also note that some of the shares being registered for resale were purchased by the selling securityholders for prices considerably below the current market price of the Common Stock. Highlight the significant negative impact sales of shares on this registration statement could have on the public trading price of the Common Stock. Risk Factors, page 17 4.Include an additional risk factor highlighting the negative pressure potential sales of shares pursuant to this registration statement could have on the public trading price of the common stock. To illustrate this risk, disclose the purchase price of the securities being registered for resale and the percentage that these shares currently represent of the total number of shares outstanding. Also disclose that even though the current trading price is significantly below the SPAC IPO price, the private investors have an incentive to sell because they will still profit on sales because of the lower price that they purchased their shares than the public investors. Management’s Discussion and Analysis of Financial Condition and Results of Operations of ProSomnus Proposed Business Combination Transaction, page 58 5.We note your disclosure of the "Proposed Business Combination Transaction" of Lakeshore and ProSomnus. We also note your reference to a section titled "Selected Historical Combined Financial Information of ProSomnus." Please update this section to reflect the current state of your business's operations and financial position, as your proposed business combination has been successfully completed. Overview, page 60 6.In light of the significant number of redemptions and the unlikelihood that the company will receive significant proceeds from exercises of the warrants because of the disparity between the exercise price of the warrants and the current trading price of the Common Stock, expand your discussion of capital resources to address any changes in the company’s liquidity position since the business combination. We also note that you will likely need to raise additional capital through the sale of equity or borrowings. Please discuss the effect of this offering on the company’s ability to raise additional capital. 7.Please expand your discussion here to reflect the fact that this offering involves the potential sale of a substantial portion of shares for resale and discuss how such sales could impact the market price of the company’s common stock. Your discussion should highlight the fact that HealthpointCapital Partners II, LP, a beneficial owner of 41.5% of your outstanding shares, will be able to sell all of its shares for so long as the registration statement of which this prospectus forms a part is available for use.

FirstName LastNameLen Liptak Comapany NameProSomnus, Inc. January 24, 2023 Page 3 FirstName LastName Len Liptak ProSomnus, Inc. January 24, 2023 Page 3 Liquidity and Capital Resources, page 65 8.We note your disclosure on pages 66 and 67 of multiple contractual obligations that are conditioned "upon completion of a successful business combination" or "upon completion of a successful transaction." Please update your disclosure of all of these obligations now that the business combination has been completed. General 9.Revise your prospectus to disclose the price that each selling securityholder paid for the securities being registered for resale. Highlight any differences in the current trading price, the prices that the Sponsor, private placement investors, PIPE investors and other selling securityholders acquired their shares and warrants, and the price that the public securityholders acquired their shares and warrants. Disclose that while the Sponsor, private placement investors, PIPE investors and other selling securityholders may experience a positive rate of return based on the current trading price, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price. Please also disclose the potential profit the selling securityholders will earn based on the current trading price. Lastly, please include appropriate risk factor disclosure. 10.Please revise to update your disclosures throughout the filing and address areas that appear to need updating or that present inconsistencies. Non-exclusive examples of areas where disclosure should be updated are as follows: •On page 36, you state that "Following the consummation of the Business Combination, we intend to file and maintain an effective registration statement under the Securities Act covering such securities. The registration of these securities will permit the public resale of such securities. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our securities post-Business Combination." This statement should be updated given that this prospectus is facilitating registration of those sales.

FirstName LastNameLen Liptak Comapany NameProSomnus, Inc. January 24, 2023 Page 4 FirstName LastName Len Liptak ProSomnus, Inc. January 24, 2023 Page 4 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Jordan Nimitz at 202-551-5831 or Margaret Schwartz at 202-551-7153 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Peter Strand, Esq.

Show Raw Text
United States securities and exchange commission logo
January 24, 2023
Len Liptak
Chief Executive Officer
ProSomnus, Inc.
5860 West Las Positas Blvd., Suite 25
Pleasanton, California, 94588
Re:ProSomnus, Inc.
Registration Statement on Form S-1
Filed January 9, 2023
File No. 333-269156
Dear Len Liptak:
            We have limited our review of your registration statement to those issues we have
addressed in our comments.  In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Form S-1 filed January 9, 2023
Cover Page
1.For each of the securities being registered for resale, disclose the price that each of the
selling security holders paid for such securities.
2.Disclose the exercise price of the warrants compared to the market price of the underlying
Common Stock. If the warrants are out the money, please disclose the likelihood that
warrant holders will not exercise their warrants. Provide similar disclosure in the
prospectus summary, risk factors, MD&A and use of proceeds section and disclose that
cash proceeds associated with the exercises of the warrants are dependent on the stock
price. As applicable, describe the impact on your liquidity and update the discussion on
the ability of your company to fund your operations on a prospective basis with your
current cash on hand.

 FirstName LastNameLen Liptak
 Comapany NameProSomnus, Inc.
 January 24, 2023 Page 2
 FirstName LastNameLen Liptak
ProSomnus, Inc.
January 24, 2023
Page 2
3.We note the significant number of redemptions of your Common Stock in connection with
your business combination and that the shares being registered for resale will constitute a
considerable percentage of your public float. We also note that some of the shares being
registered for resale were purchased by the selling securityholders for prices considerably
below the current market price of the Common Stock. Highlight the significant negative
impact sales of shares on this registration statement could have on the public trading price
of the Common Stock.
Risk Factors, page 17
4.Include an additional risk factor highlighting the negative pressure potential sales of
shares pursuant to this registration statement could have on the public trading price of the
common stock. To illustrate this risk, disclose the purchase price of the securities being
registered for resale and the percentage that these shares currently represent of the total
number of shares outstanding. Also disclose that even though the current trading price
is significantly below the SPAC IPO price, the private investors have an incentive to sell
because they will still profit on sales because of the lower price that they purchased their
shares than the public investors.
Management’s Discussion and Analysis of Financial Condition and Results of Operations of
ProSomnus
Proposed Business Combination Transaction, page 58
5.We note your disclosure of the "Proposed Business Combination Transaction" of
Lakeshore and ProSomnus. We also note your reference to a section titled "Selected
Historical Combined Financial Information of ProSomnus." Please update this section to
reflect the current state of your business's operations and financial position, as your
proposed business combination has been successfully completed.
Overview, page 60
6.In light of the significant number of redemptions and the unlikelihood that the company
will receive significant proceeds from exercises of the warrants because of the disparity
between the exercise price of the warrants and the current trading price of the Common
Stock, expand your discussion of capital resources to address any changes in the
company’s liquidity position since the business combination. We also note that you will
likely need to raise additional capital through the sale of equity or borrowings. Please
discuss the effect of this offering on the company’s ability to raise additional capital.
7.Please expand your discussion here to reflect the fact that this offering involves the
potential sale of a substantial portion of shares for resale and discuss how such sales could
impact the market price of the company’s common stock. Your discussion should
highlight the fact that HealthpointCapital Partners II, LP, a beneficial owner of 41.5% of
your outstanding shares, will be able to sell all of its shares for so long as the registration
statement of which this prospectus forms a part is available for use.

 FirstName LastNameLen Liptak
 Comapany NameProSomnus, Inc.
 January 24, 2023 Page 3
 FirstName LastName
Len Liptak
ProSomnus, Inc.
January 24, 2023
Page 3
Liquidity and Capital Resources, page 65
8.We note your disclosure on pages 66 and 67 of multiple contractual obligations that are
conditioned "upon completion of a successful business combination" or "upon completion
of a successful transaction." Please update your disclosure of all of these obligations now
that the business combination has been completed.
General
9.Revise your prospectus to disclose the price that each selling securityholder paid for the
securities being registered for resale. Highlight any differences in the current trading
price, the prices that the Sponsor, private placement investors, PIPE investors and other
selling securityholders acquired their shares and warrants, and the price that the public
securityholders acquired their shares and warrants. Disclose that while the Sponsor,
private placement investors, PIPE investors and other selling securityholders may
experience a positive rate of return based on the current trading price, the public
securityholders may not experience a similar rate of return on the securities they
purchased due to differences in the purchase prices and the current trading price. Please
also disclose the potential profit the selling securityholders will earn based on the current
trading price. Lastly, please include appropriate risk factor disclosure.
10.Please revise to update your disclosures throughout the filing and address areas that
appear to need updating or that present inconsistencies. Non-exclusive examples of areas
where disclosure should be updated are as follows:
•On page 36, you state that "Following the consummation of the Business
Combination, we intend to file and maintain an effective registration statement under
the Securities Act covering such securities. The registration of these securities will
permit the public resale of such securities. The registration and availability of such a
significant number of securities for trading in the public market may have an adverse
effect on the market price of our securities post-Business Combination." This
statement should be updated given that this prospectus is facilitating registration of
those sales.

 FirstName LastNameLen Liptak
 Comapany NameProSomnus, Inc.
 January 24, 2023 Page 4
 FirstName LastName
Len Liptak
ProSomnus, Inc.
January 24, 2023
Page 4
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            Please contact Jordan Nimitz at 202-551-5831 or Margaret Schwartz at 202-551-7153
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Peter Strand, Esq.